TARO - TARO PHARM INDUS （）

StockNews.com upgraded shares of Taro Pharmaceutical Industries (NYSE:TARO – Get Rating) from a hold rating to a buy rating in a research note published on Tuesday. Separately, HC Wainwright cut their target price on Taro Pharmaceutical Industries from $54.00 to $35.00 and set a buy rating for the company in a research note on Wednesday, […]

Taro Pharmaceutical''s quarterly numbers came in with very thin growth at the operating and bottom-lines. Read more to learn why TARO stock is currently a Hold.

Taro Pharma Misses Q4 EPS by 68c

Taro Pharmaceutical press release (NYSE:TARO): Q3 GAAP EPS of $0.19 misses by $0.68.Revenue of $139.2M misses by $23.92M.

Taro Pharmaceutical Indus (NYSE: TARO ) is set to give its latest quarterly earnings report on Tuesday, 2023-01-24. Here''s what investors need to know before the announcement. Analysts estimate that Taro Pharmaceutical Indus will report an earnings per share (EPS) of $0.87. Taro Pharmaceutical Indus bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com

Taro Pharma Misses Q4 EPS by 68c

Taro Pharmaceutical press release (NYSE:TARO): Q3 GAAP EPS of $0.19 misses by $0.68.Revenue of $139.2M misses by $23.92M.

Taro Pharmaceutical Indus (NYSE: TARO ) is set to give its latest quarterly earnings report on Tuesday, 2023-01-24. Here''s what investors need to know before the announcement. Analysts estimate that Taro Pharmaceutical Indus will report an earnings per share (EPS) of $0.87. Taro Pharmaceutical Indus bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com

The operational performance, however, will be hit by higher research and development costs, input prices, and continued erosion in prices in the US generics market. Sun Pharma’s US-based subsidiary Taro Pharmaceutical Industries, which released Q2 earnings last week, reported an operating loss of $6.8 million against a profit of $24.4 million a year ago, primarily due to pricing pressure in the generics drug market.

Taro Pharmaceutical press release (TARO): FQ2 Non-GAAP EPS of $0.66 misses by $0.18.Revenue of $130.5M (-11.3% Y/Y) misses by $30.52M.Gross profit of $47.0M (36.0% of net…

Taro Pharmaceutical press release (TARO): Q4 GAAP EPS of $0.73.Revenue of $143.26M (-3.4% Y/Y).

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The quarter ended March 31, 2022, includes one month’s results from the February 28th acquisition of Alchemee. Net sales of $143.3 million

Taro Pharmaceutical Industries (TARO) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 26.9% year-to-date, down 47.9% over the past 12 months, and down 60.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.8%, and the S&P 500 rose 1.4%. Trading Activity Trading volume this week was 105.3% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -445.6% The company's stock price performance over the past 12 months lags the peer average by -421.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Taro Pharmaceutical (TARO) is scheduled to announce Q1 earnings results on Thursday, May 26th, after market close.The consensus EPS Estimate is $0.88 (+8.6% Y/Y) and the consensus…

Posted by Equitymaster Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note. Benchmark indices added to yesterday''s gains following a clawback in European markets and US futures as smart investors saw value in the current market valuations. The Sensex reclaimed 54,600 levels while the Nifty clawed back to 16,300 levels led by media, realty, and auto stocks. The sharp rally comes on hopes of de-escalation of the Russia-Ukraine conflict after the Ukrainian President Zelenskyy indicated that the country was no longer interest in NATO membership, the main reason behind the war. At the closing bell, the BSE Sensex stood higher by 1,223 points (up 2.3%). Meanwhile, the NSE Nifty closed higher by 332 points (up 2.1%). Asian Paints and Reliance Industries were among the top gainers today . Shree Cement and ONGC, on the other hand, were among the top losers today . The SGX Nifty was trading at 16,350, up by 408 points, at the time of writing.